In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

From bench to practice: hypertension control

Session presentations
Hypertension


J. Redon argued that chronic kidney disease is a high risk condition, in which treatment-resistant hypertension plays a major role, particularly when confirmed by ambulatory BP monitoring. In CKD stage 3-4, systolic office BP and 24-h BP were not controlled in respectively 63% and 86% of the patients, due to volume overload, sympathetic overactivity and structural vascular changes. The management of resistant hypertension involves amongst others, salt restriction and careful optimization of diuretic therapy with loop diuretics and spironolactone; the role of renal denervation is currently being assessed.

According to R. Cifkova, hypertension complicates about 10% of pregnancies, either as pre-existing hypertension, gestational hypertension or, in case of significant proteinuria, pre-eclampsia, and is the major cause of maternal, fetal and neonatal morbidity and mortality. Women at risk for pre-eclampsia are advised to take 75 mg of aspirin/day from 12 weeks until birth.

Pharmacological therapy, with exclusion of RAS blockers, is in general indicated when BP is > 150/95 mmHg, but a number of special conditions require treatment at 140/90 mmHg.

Stroke is the major complication of hypertension and there is ample evidence that antihypertensive treatment reduces the incidence of stroke, A. Coca said. Whereas there is in general no evidence that BP should be lowered below 130/80 mmHg in hypertensive patients, this lower BP may have some benefit for the primary prevention of stroke, but this is not clear for prevention of recurrent stroke. The best management for high blood pressure during acute stroke is still under investigation.

Finally M. Dorobantu discussed that there is probably a bottom level for cardiovascular risk reduction during antihypertensive treatment, but that certain antihypertensive agents provide clinical benefit independent of their effect on BP, with particularly emphasis on RAS blockers and calcium channel blockers.

References


944

SessionTitle:

From bench to practice: hypertension control

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.